Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: Effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea

Cytochrome P450 2D6 (CYP2D6), an important CYP isoform with regard to drug-drug interactions, accounts for the metabolism of [thick similar]30% of all medications. To date, few studies have assessed the effects of botanical supplementation on human CYP2D6 activity in vivo. Six botanical extracts wer...

Full description

Saved in:
Bibliographic Details
Published inMolecular nutrition & food research Vol. 52; no. 7; pp. 755 - 763
Main Authors Gurley, Bill J, Swain, Ashley, Hubbard, Martha A, Williams, D. Keith, Barone, Gary, Hartsfield, Faith, Tong, Yudong, Carrier, Danielle J, Cheboyina, Shreekar, Battu, Sunil K
Format Journal Article
LanguageEnglish
Published Weinheim Wiley-VCH Verlag 01.07.2008
WILEY-VCH Verlag
WILEY‐VCH Verlag
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Cytochrome P450 2D6 (CYP2D6), an important CYP isoform with regard to drug-drug interactions, accounts for the metabolism of [thick similar]30% of all medications. To date, few studies have assessed the effects of botanical supplementation on human CYP2D6 activity in vivo. Six botanical extracts were evaluated in three separate studies (two extracts per study), each incorporating 16 healthy volunteers (eight females). Subjects were randomized to receive a standardized botanical extract for 14 days on separate occasions. A 30-day washout period was interposed between each supplementation phase. In study 1, subjects received milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa). In study 2, kava kava (Piper methysticum) and goldenseal (Hydrastis canadensis) extracts were administered, and in study 3 subjects received St. John's wort (Hypericum perforatum) and Echinacea (Echinacea purpurea). The CYP2D6 substrate, debrisoquine (5 mg), was administered before and at the end of supplementation. Pre- and post-supplementation phenotypic trait measurements were determined for CYP2D6 using 8-h debrisoquine urinary recovery ratios (DURR). Comparisons of pre- and post-supplementation DURR revealed significant inhibition ([thick similar]50%) of CYP2D6 activity for goldenseal, but not for the other extracts. Accordingly, adverse herb-drug interactions may result with concomitant ingestion of goldenseal supplements and drugs that are CYP2D6 substrates.
Bibliography:http://dx.doi.org/10.1002/mnfr.200600300
NIH/NIGMS - No. RO1 GM71322
NIH/NCRR - No. M01 RR14288
istex:B08A99F4E40C835CF838698D98F8EDB4F4F0BF25
ArticleID:MNFR200600300
ark:/67375/WNG-46DB258X-8
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1613-4125
1613-4133
1613-4133
DOI:10.1002/mnfr.200600300